参考文献: 1. 2022 EBMT ABSTRACT OS08-01: LONG-TERM FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INH...
An Interim Analysis of the ZUMA-1 Study of KTE-C19 in Refractory, Aggressive Non-Hodgkin LymphomaO'Brien, SusanClinical Advances in Hematology & Oncology
Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)...
6、Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes ( Protégé study) : 1-year results from a randomised,placebo-controlled trial[J] . Lancet, 2011, 378( 9790) : 487-497
Uses Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC)[1]. References [1] Pal SK, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with...
Study (UltIMMa-2 vs UltIMMa-1)0.97.881.14.460.68.260.75.091.01.960.76.110.77.16 Prior biologic use (0 vs ≥1)0.83.300.64.020.53.070.75.100.94.761.58.011.03.87 PRO baseline value0.93.0030.90<.0011.16<.0010.94<.0010<.0011.26<.0011.25<.001 ...
Patients with advanced gastric cancer typically face a grim prognosis. This phase 1a (dose escalation) and phase 1b (dose expansion) study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapy for advanced gastric or
[1]Shen L,et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or linkstatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study[J]. Journal of clinical oncology, 2022, 40(26): 3065-3076. ...
Efficacy and safety study of Camrelizumab in combination with neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced cervical cancer 开始日期2025-05-06 申办/合作机构- ChiCTR2500101420 / Suspended临床2期IIT A single-arm, single-center, open, prospective phase II clinical study of...
Low-dose otelixizumab was safe but did not preserve beta-cell function in patients with newly diagnosed type 1 diabetes in a phase 3 trial; GSK has started a new dosing study.